Literature DB >> 23652584

Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: a time course analysis.

P M Becher1, D Lindner, M Fröhlich, K Savvatis, D Westermann, C Tschöpe.   

Abstract

In this study, we examined cardiac inflammation, fibrosis and left ventricular (LV) function during the development of streptozotocin (STZ)-induced diabetic cardiomyopathy using an animal model of diabetes mellitus (DM). Diabetes was induced in 22 Sprague‑Dawley rats by an intraperitoneal single injection of STZ (70 mg/kg). Non-diabetic animals served as the controls (n=6). LV function was documented using the conductance catheter technique 2 and 6 weeks after the induction of diabetes. Cardiac tissue was analyzed for cardiac immune cell infiltration, oxidative stress and remodeling in rats with STZ-induced diabetes at 2 different time points by immunohistochemistry. Cardiac function was significantly impaired in the diabetic animals. After 2 weeks, the induction of diabetes resulted in impaired cardiac function indexed by a decrease in systolic and diastolic LV function. This impairment of LV performance continued for up to 6 weeks after the STZ injection. This was associated with an increase in cardiac CD3+ and CD8a+ immune cell invasion and fibrosis, indexed by an increase in collagen content (p<0.05). Furthermore, oxidative stress response and matrix remodeling were increased after 2 weeks and this continued for up to 6 weeks after the induction of diabetes. In conclusion, cardiac dysfunction is associated with cardiac inflammation and adverse remodeling in experimental diabetic cardiomyopathy. Our results suggest that the model of STZ-induced diabetic cardiomyopathy is a robust model for investigating cardiac immune response and LV remodeling processes under diabetic conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652584     DOI: 10.3892/ijmm.2013.1368

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

1.  Nobiletin attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin: induced diabetic cardiomyopathy.

Authors:  Ning Zhang; Zheng Yang; Shi-Zhao Xiang; Ya-Ge Jin; Wen-Ying Wei; Zhou-Yan Bian; Wei Deng; Qi-Zhu Tang
Journal:  Mol Cell Biochem       Date:  2016-05-10       Impact factor: 3.396

2.  Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy.

Authors:  Aina He; Wenqian Fang; Kun Zhao; Yajun Wang; Jie Li; Chongzhe Yang; Feriel Benadjaoud; Guo-Ping Shi
Journal:  Transl Res       Date:  2019-01-19       Impact factor: 7.012

Review 3.  Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.

Authors:  Zoltán V Varga; Zoltán Giricz; Lucas Liaudet; György Haskó; Peter Ferdinandy; Pál Pacher
Journal:  Biochim Biophys Acta       Date:  2014-07-02

4.  Mitochondrial dysfunction in brain cortex mitochondria of STZ-diabetic rats: effect of l-Arginine.

Authors:  M Del Carmen Ortiz; Silvia Lores-Arnaiz; M Florencia Albertoni Borghese; Sabrina Balonga; Agustina Lavagna; Ana Laura Filipuzzi; Daniela Cicerchia; Monica Majowicz; Juanita Bustamante
Journal:  Neurochem Res       Date:  2013-11-05       Impact factor: 3.996

5.  The co-occurrence of myocardial dysfunction and peripheral insensate neuropathy in a streptozotocin-induced rat model of diabetes.

Authors:  Maria N Marangoni; Scott T Brady; Shamim A Chowdhury; Mariann R Piano
Journal:  Cardiovasc Diabetol       Date:  2014-01-11       Impact factor: 9.951

6.  Hyperglycemia-Induced Hypovolemia Is Involved in Early Cardiac Magnetic Resonance Alterations in Streptozotocin-Induced Diabetic Mice: A Comparison with Furosemide-Induced Hypovolemia.

Authors:  Michael Joubert; Dimitri Bellevre; Damien Legallois; Nicolas Elie; Laurent Coulbault; Stéphane Allouche; Alain Manrique
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

7.  Parenchymal and Stromal Cells Contribute to Pro-Inflammatory Myocardial Environment at Early Stages of Diabetes: Protective Role of Resveratrol.

Authors:  Monia Savi; Leonardo Bocchi; Roberto Sala; Caterina Frati; Costanza Lagrasta; Denise Madeddu; Angela Falco; Serena Pollino; Letizia Bresciani; Michele Miragoli; Massimiliano Zaniboni; Federico Quaini; Daniele Del Rio; Donatella Stilli
Journal:  Nutrients       Date:  2016-11-16       Impact factor: 5.717

8.  Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor.

Authors:  Peter Moritz Becher; Svenja Hinrichs; Nina Fluschnik; Jan K Hennigs; Karin Klingel; Stefan Blankenberg; Dirk Westermann; Diana Lindner
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

Review 9.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

10.  Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats.

Authors:  Hong Li; Yunfei Bian; Nana Zhang; Jia Guo; Cheng Wang; Wayne Bond Lau; Chuanshi Xiao
Journal:  Cardiovasc Diabetol       Date:  2013-06-18       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.